-
1
-
-
0029100397
-
Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
-
Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RG, Habus I, Jlang Z, Iyer RP, Yu D, and Zhang R (1995). Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50: 571-576.
-
(1995)
Biochem. Pharmacol.
, vol.50
, pp. 571-576
-
-
Agrawal, S.1
Zhang, X.2
Lu, Z.3
Zhao, H.4
Tamburin, J.M.5
Yan, J.6
Cai, H.7
Diasio, R.G.8
Habus, I.9
Jlang, Z.10
Iyer, R.P.11
Yu, D.12
Zhang, R.13
-
2
-
-
0029791763
-
Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors
-
Altmann KH, Fabbro D, Dean NM, Geiger T, Monia BP, Muuler M, and Nicklin P (1996). Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors. Biochem. Soc. Trans. 24: 630-637.
-
(1996)
Biochem. Soc. Trans.
, vol.24
, pp. 630-637
-
-
Altmann, K.H.1
Fabbro, D.2
Dean, N.M.3
Geiger, T.4
Monia, B.P.5
Muuler, M.6
Nicklin, P.7
-
3
-
-
0031912506
-
Antisense oligonucleotides: Is the glass half full or half empty?
-
Bennett CF (1998). Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol. 55: 9-19.
-
(1998)
Biochem. Pharmacol.
, vol.55
, pp. 9-19
-
-
Bennett, C.F.1
-
4
-
-
0030980684
-
An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
-
Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, and Jacoby HI (1997). An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280: 988-1000.
-
(1997)
J. Pharmacol. Exp. Ther.
, vol.280
, pp. 988-1000
-
-
Bennett, C.F.1
Kornbrust, D.2
Henry, S.3
Stecker, K.4
Howard, R.5
Cooper, S.6
Dutson, S.7
Hall, W.8
Jacoby, H.I.9
-
5
-
-
0030222182
-
Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid
-
Bennett CF, Zuckerman JE, Kornbrust D, Sasmor H, Leeds JM, and Crooke ST (1996). Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J. Controlled Release 41: 121-130.
-
(1996)
J. Controlled Release
, vol.41
, pp. 121-130
-
-
Bennett, C.F.1
Zuckerman, J.E.2
Kornbrust, D.3
Sasmor, H.4
Leeds, J.M.5
Crooke, S.T.6
-
6
-
-
0027481659
-
Progress toward oligonucleotide therapeutics: Pharmacodynamic properties
-
Crooke ST (1993). Progress toward oligonucleotide therapeutics: Pharmacodynamic properties. FASEB 7: 533-539.
-
(1993)
FASEB
, vol.7
, pp. 533-539
-
-
Crooke, S.T.1
-
7
-
-
0001675653
-
Oligonucleotide therapeutics
-
5th ed., ME Wolff (ed). Wiley and Sons, New York
-
Crooke ST (1995). Oligonucleotide therapeutics. In: Burger's Medicinal Chemistry and Drug Discovery, Vol. 1, 5th ed., ME Wolff (ed). Wiley and Sons, New York, pp. 863-900.
-
(1995)
Burger's Medicinal Chemistry and Drug Discovery
, vol.1
, pp. 863-900
-
-
Crooke, S.T.1
-
8
-
-
12644302203
-
Pharmacokinetic properties of several novel oligonucleotide analogs in mice
-
Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, and Griffey RH (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277: 923-937.
-
(1996)
J. Pharmacol. Exp. Ther.
, vol.277
, pp. 923-937
-
-
Crooke, S.T.1
Graham, M.J.2
Zuckerman, J.E.3
Brooks, D.4
Conklin, B.S.5
Cummins, L.L.6
Greig, M.J.7
Guinosso, C.J.8
Kornbrust, D.9
Manoharan, M.10
Sasmor, H.M.11
Schleich, T.12
Tivel, K.L.13
Griffey, R.H.14
-
9
-
-
0030839546
-
Identification and characterization of second-generation antisense oligonucleotides
-
Dean NM and Griffey RH (1997). Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7: 229-233.
-
(1997)
Antisense Nucleic Acid Drug Dev.
, vol.7
, pp. 229-233
-
-
Dean, N.M.1
Griffey, R.H.2
-
10
-
-
0028062847
-
Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
-
Dean NM and McKay R (1994). Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91: 11762-11766.
-
(1994)
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 11762-11766
-
-
Dean, N.M.1
McKay, R.2
-
11
-
-
0015150973
-
Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice
-
Diamantstein T, Wagner B, Beyse I, Odenwald MV, and Schultz G (1971). Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice. Eur. J. Immunol. 1: 340-343.
-
(1971)
Eur. J. Immunol.
, vol.1
, pp. 340-343
-
-
Diamantstein, T.1
Wagner, B.2
Beyse, I.3
Odenwald, M.V.4
Schultz, G.5
-
12
-
-
0028596461
-
Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
-
Galbraith WM, Hobson WC, Giclas PC, Schlechter PJ, and Agrawal S (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4: 201-206.
-
(1994)
Antisense Res. Dev.
, vol.4
, pp. 201-206
-
-
Galbraith, W.M.1
Hobson, W.C.2
Giclas, P.C.3
Schlechter, P.J.4
Agrawal, S.5
-
13
-
-
0030667690
-
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
-
Geary RS, Leeds JM, Fitchett J, Burckin T, Troung L, Spainhour C, Creek M, and Levin AA (1997). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25: 1272-1281.
-
(1997)
Drug Metab. Dispos.
, vol.25
, pp. 1272-1281
-
-
Geary, R.S.1
Leeds, J.M.2
Fitchett, J.3
Burckin, T.4
Troung, L.5
Spainhour, C.6
Creek, M.7
Levin, A.A.8
-
14
-
-
0030797704
-
Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
-
Geary RS, Leeds JM, Henry SP, Monteith DM, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 383-394.
-
(1997)
Anti-Cancer Drug Des.
, vol.12
, pp. 383-394
-
-
Geary, R.S.1
Leeds, J.M.2
Henry, S.P.3
Monteith, D.M.4
Levin, A.A.5
-
15
-
-
0003817056
-
New twists on nucleic acids: Structural properties of modified nucleosides incorporated into oligonucleotides
-
YS Sanghvi and PD Cook (eds). American Chemical Society, Washington, D.C.
-
Griffey RH, Lesnik E, Frier S, Sanghvi YS, Teng K, Kawasaki A, Guinoso C, Wheeler P, Mohan V, and Cook PD (1994). New twists on nucleic acids: Structural properties of modified nucleosides incorporated into oligonucleotides. In Carbohydrate Modifications in Antisense Research, Vol. 580, YS Sanghvi and PD Cook (eds). American Chemical Society, Washington, D.C., pp. 212-224.
-
(1994)
Carbohydrate Modifications in Antisense Research
, vol.580
, pp. 212-224
-
-
Griffey, R.H.1
Lesnik, E.2
Frier, S.3
Sanghvi, Y.S.4
Teng, K.5
Kawasaki, A.6
Guinoso, C.7
Wheeler, P.8
Mohan, V.9
Cook, P.D.10
-
16
-
-
0030918233
-
Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys
-
Henry SP, Bolte H, Auletta C, and Kornbrust DJ (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120: 145-155.
-
(1997)
Toxicology
, vol.120
, pp. 145-155
-
-
Henry, S.P.1
Bolte, H.2
Auletta, C.3
Kornbrust, D.J.4
-
17
-
-
0030922755
-
Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action
-
Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, and Kornbrust DJ (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther. 281: 810-816.
-
(1997)
J. Pharmacol. Exp. Ther.
, vol.281
, pp. 810-816
-
-
Henry, S.P.1
Giclas, P.C.2
Leeds, J.3
Pangburn, M.4
Auletta, C.5
Levin, A.A.6
Kornbrust, D.J.7
-
18
-
-
0031036843
-
Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats
-
Henry SP, Grillone LR, Orr JL, Brunner RH, and Kornbrust DJ (1997). Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology 116: 77-88.
-
(1997)
Toxicology
, vol.116
, pp. 77-88
-
-
Henry, S.P.1
Grillone, L.R.2
Orr, J.L.3
Brunner, R.H.4
Kornbrust, D.J.5
-
19
-
-
0030860587
-
Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides
-
Henry SP, Monteith D, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 395-408.
-
(1997)
Anti-Cancer Drug Des.
, vol.12
, pp. 395-408
-
-
Henry, S.P.1
Monteith, D.2
Levin, A.A.3
-
20
-
-
0030829919
-
Inhibition of coagulation by a phosphorothioate oligonucleotide
-
Henry SP, Novotny W, Leeds J, Auletta C, and Kornbrust DJ (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7: 503-510.
-
(1997)
Antisense Nucleic Acid Drug Dev.
, vol.7
, pp. 503-510
-
-
Henry, S.P.1
Novotny, W.2
Leeds, J.3
Auletta, C.4
Kornbrust, D.J.5
-
21
-
-
0030806664
-
Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice
-
Henry SP, Taylor J, Midgley L, Levin AA, and Kornbrust DJ (1997). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7: 473-481.
-
(1997)
Antisense Nucleic Acid Drug Dev.
, vol.7
, pp. 473-481
-
-
Henry, S.P.1
Taylor, J.2
Midgley, L.3
Levin, A.A.4
Kornbrust, D.J.5
-
22
-
-
0015441952
-
Studies on poly I: C toxicity in experimental animals
-
Homan ER, Zendzian RP, Schott LD, Levy HB, and Adamson RH (1972). Studies on poly I: C toxicity in experimental animals. Toxicol. Appl. Pharmacol. 23: 579-588.
-
(1972)
Toxicol. Appl. Pharmacol.
, vol.23
, pp. 579-588
-
-
Homan, E.R.1
Zendzian, R.P.2
Schott, L.D.3
Levy, H.B.4
Adamson, R.H.5
-
23
-
-
0010077392
-
Evaluation of the renal effects of phosphorothioate oligonucleotides in monkeys
-
abstract
-
Horner MJ, Monteith DK, Gillett NA, Butler M, Henry SP, Bennett CF, and Levin AA (1997). Evaluation of the renal effects of phosphorothioate oligonucleotides in monkeys. Fundam. Appl. Toxicol. 36(suppl.): 147 (abstract).
-
(1997)
Fundam. Appl. Toxicol.
, vol.36
, Issue.SUPPL.
, pp. 147
-
-
Horner, M.J.1
Monteith, D.K.2
Gillett, N.A.3
Butler, M.4
Henry, S.P.5
Bennett, C.F.6
Levin, A.A.7
-
24
-
-
0027052546
-
Oligonucleotide sequences required for natural killer cell activation
-
Kuramoto E, Yano O, Kimura Y, Baba M, Makino T, Yamamoto S, Yamamoto T, Kataoka T, and Tokonaga T (1992). Oligonucleotide sequences required for natural killer cell activation. Jpn. J. Cancer Res. 83: 1128-1131.
-
(1992)
Jpn. J. Cancer Res.
, vol.83
, pp. 1128-1131
-
-
Kuramoto, E.1
Yano, O.2
Kimura, Y.3
Baba, M.4
Makino, T.5
Yamamoto, S.6
Yamamoto, T.7
Kataoka, T.8
Tokonaga, T.9
-
25
-
-
0029873193
-
Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice
-
Leonetti C, Dagnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro G, and Zupi G (1996). Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst. 88: 419-429.
-
(1996)
J. Natl. Cancer Inst.
, vol.88
, pp. 419-429
-
-
Leonetti, C.1
Dagnano, I.2
Lozupone, F.3
Valentini, A.4
Geiser, T.5
Zon, G.6
Calabretta, B.7
Citro, G.8
Zupi, G.9
-
26
-
-
0029933947
-
Recent status of the antisense oligonucleotide approaches in oncology
-
Ma L and Calvo F (1996). Recent status of the antisense oligonucleotide approaches in oncology. Fundam. Clin. Pharmacol. 10: 97-115.
-
(1996)
Fundam. Clin. Pharmacol.
, vol.10
, pp. 97-115
-
-
Ma, L.1
Calvo, F.2
-
27
-
-
0031445426
-
Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides
-
Mandiyan S, Schumacher C, Cioffi C, Sharif H, Yuryev A, Lappe R, Monia B, Hanson S, Goff S, and Wennogle L (1997). Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7: 539-548.
-
(1997)
Antisense Nucleic Acid Drug Dev.
, vol.7
, pp. 539-548
-
-
Mandiyan, S.1
Schumacher, C.2
Cioffi, C.3
Sharif, H.4
Yuryev, A.5
Lappe, R.6
Monia, B.7
Hanson, S.8
Goff, S.9
Wennogle, L.10
-
28
-
-
9844254479
-
Conjugated antisense oligonucleotides
-
Manoharan M, Tivel KL, Condon TP, Andrade LK, Barber-Peoch I, Inanmati G, Shah S, Mohan V, Graham MJ, Bennett CF, Crooke ST, and Cook PD (1997). Conjugated antisense oligonucleotides. Nucleosides Nucleotides 16: 1129-1138.
-
(1997)
Nucleosides Nucleotides
, vol.16
, pp. 1129-1138
-
-
Manoharan, M.1
Tivel, K.L.2
Condon, T.P.3
Andrade, L.K.4
Barber-Peoch, I.5
Inanmati, G.6
Shah, S.7
Mohan, V.8
Graham, M.J.9
Bennett, C.F.10
Crooke, S.T.11
Cook, P.D.12
-
29
-
-
0345028189
-
Renal toxicity of phosphorothioate oligonucleotides in rats
-
abstract
-
Manza LL, Butler MM, Bennett CF, Levin AA, de Peyster AA, and Monteith DK (1997). Renal toxicity of phosphorothioate oligonucleotides in rats. Fundam. Appl. Toxicol. 36(suppl.): 147 (abstract).
-
(1997)
Fundam. Appl. Toxicol.
, vol.36
, Issue.SUPPL.
, pp. 147
-
-
Manza, L.L.1
Butler, M.M.2
Bennett, C.F.3
Levin, A.A.4
De Peyster, A.A.5
Monteith, D.K.6
-
30
-
-
12644268252
-
Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human c-raf kinase supports an antisense mechanism of action in vivo
-
Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, and Fabbro D (1996). Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human c-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93: 15481-15484.
-
(1996)
Proc. Natl. Acad. Sci. USA
, vol.93
, pp. 15481-15484
-
-
Monia, B.P.1
Sasmor, H.2
Johnston, J.F.3
Freier, S.M.4
Lesnik, E.A.5
Muller, M.6
Geiger, T.7
Altmann, K.H.8
Moser, H.9
Fabbro, D.10
-
31
-
-
0032430114
-
Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys
-
in press
-
Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, and Levin AA (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. 46: (in press).
-
(1998)
Toxicol. Sci.
, vol.46
-
-
Monteith, D.K.1
Geary, R.S.2
Leeds, J.M.3
Johnston, J.4
Monia, B.P.5
Levin, A.A.6
-
32
-
-
0030842828
-
Immune stimulation - A class effect of phosphorothioate oligodeoxynucleotides in rodents
-
Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, and Crooke ST (1997). Immune stimulation - A class effect of phosphorothioate oligodeoxynucleotides in rodents. AntiCancer Drug Des. 12: 421-432.
-
(1997)
Anticancer Drug Des.
, vol.12
, pp. 421-432
-
-
Monteith, D.K.1
Henry, S.P.2
Howard, R.B.3
Flournoy, S.4
Levin, A.A.5
Bennett, C.F.6
Crooke, S.T.7
-
33
-
-
0030776403
-
Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
-
Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, and Nicklin PL (1997). Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54: 657-668.
-
(1997)
Biochem. Pharmacol.
, vol.54
, pp. 657-668
-
-
Phillips, J.A.1
Craig, S.J.2
Bayley, D.3
Christian, R.A.4
Geary, R.5
Nicklin, P.L.6
-
34
-
-
0027954331
-
Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus
-
Pisetsky DS and Reich CF (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54: 101-107.
-
(1994)
Life Sci.
, vol.54
, pp. 101-107
-
-
Pisetsky, D.S.1
Reich, C.F.2
-
36
-
-
0022544031
-
In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG
-
Shimada S, Yano O, and Tokunaga T (1986). In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn. J. Cancer Res. 77: 808-816.
-
(1986)
Jpn. J. Cancer Res.
, vol.77
, pp. 808-816
-
-
Shimada, S.1
Yano, O.2
Tokunaga, T.3
-
37
-
-
0027987972
-
Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities
-
Stepkowski SM, Tu Y, Condon TP, and Bennett CF (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 153: 5336-5346.
-
(1994)
J. Immunol.
, vol.153
, pp. 5336-5346
-
-
Stepkowski, S.M.1
Tu, Y.2
Condon, T.P.3
Bennett, C.F.4
-
38
-
-
0023683638
-
A synthetic single-stranded DNA, poly (dG, dC), induces interferon-α/β and -γ augments natural killer activity, and suppresses tumor growth
-
Tokunaga T, Yamamato S, and Namba K (1988). A synthetic single-stranded DNA, poly (dG, dC), induces interferon-α/β and -γ augments natural killer activity, and suppresses tumor growth. Jpn. J. Cancer Res. 79: 682-686.
-
(1988)
Jpn. J. Cancer Res.
, vol.79
, pp. 682-686
-
-
Tokunaga, T.1
Yamamato, S.2
Namba, K.3
-
39
-
-
0028087886
-
Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length
-
Yamamoto T, Yamamoto S, Kataoka T, and Tokunaga T (1994). Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res. Dev. 4: 119-122.
-
(1994)
Antisense Res. Dev.
, vol.4
, pp. 119-122
-
-
Yamamoto, T.1
Yamamoto, S.2
Kataoka, T.3
Tokunaga, T.4
-
40
-
-
0029833019
-
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide
-
Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL and Glazer RI (1996). Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50: 236-242.
-
(1996)
Mol. Pharmacol.
, vol.50
, pp. 236-242
-
-
Yazaki, T.1
Ahmad, S.2
Chahlavi, A.3
Zylber-Katz, E.4
Dean, N.M.5
Rabkin, S.D.6
Martuza, R.L.7
Glazer, R.I.8
|